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Abstract
Background: The purpose of this study is to assess the relative effectiveness of Interpersonal Psychotherapy (IPT),
Psychoeducative Group Therapy (PeGT), and treatment as usual (TAU) for patients with Major Depressive Disorder
(MDD) in municipal psychiatric secondary care in one Finnish region.
Methods: All adult patients (N = 1515) with MDD symptoms referred to secondary care in 2004-2006 were
screened. Eligible, consenting patients were assigned randomly to 10-week IPT (N = 46), PeGT (N = 42), or TAU
(N = 46) treatment arms. Antidepressant pharmacotherapy among study participants was evaluated. The
Hamilton Depression Rating scale (HAM-D) was the primary outcome measure. Assessment occurred at 1, 5, 3,
6, and 12 months. Actual amount of therapists’ labor was also evaluated. All statistical analyses were
performed with R software.
Results: All three treatment cells showed marked improvement at 12-month follow-up. At 3 months, 42 % in
IPT, 61 % in PeGT, and 42 % in TAU showed a mean ≥50 % in HAM-D improvement; after 12 months, these
values were 61 %, 76 %, and 68 %.
Concomitant medication and limited sample size minimized between-treatment differences. Statistically
significant differences emerged only between PeGT and TAU favoring PeGT. Secondary outcome measures
(CGI-s and SOFAS) showed parallel results.
Conclusion: All three treatments notably benefited highly comorbid MDD patients in a public sector
secondary care unit.
Trial registration: ClinicalTrials.gov NCT02314767 (09.12.2014).
Keywords: Depression, Randomized controlled trial, Effectiveness, Interpersonal Psychotherapy,
Psychoeducative Group Therapy
Background
Population surveys in Finland have found a 5 % preva-
lence of major depressive disorder (MDD), comprising
more than 200,000 Finnish adults. An additional 15 % re-
port milder depressive symptoms [1]. The prevalence of
depressive disorders in Finland resembles that in other
European countries and the United States [2, 3]. Depres-
sive disorders are inversely associated with general well-
being and health, cause serious psychosocial and work im-
pairment, and produce a substantial societal burden [4].
Depression is the most costly psychiatric disorder in
Europe, accounting for 33 % of the total cost of brain dis-
orders. This corresponds to 1 % of the total European
economy (GDP) [5]. Studies have found a temporal rela-
tionship between depression and functional disability [6].
Effective treatment can alleviate suffering and reverse
the social and occupational decline of depressed pa-
tients. Several treatment modalities have shown efficacy
in randomized clinical trials for MDD, including
pharmacotherapy, interpersonal psychotherapy (IPT),
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cognitive-behavioral therapy, and behavioral activation
therapy. Despite clinical practice guidelines issued to im-
prove the quality of antidepressant care, studies have re-
peatedly shown that a high proportion of depressed
Finnish patients receive suboptimal treatment. Only
10.6 % of depressed patients have ever received weekly
psychotherapy during their treatment period [7, 8].
Treatments with established efficacy in highly controlled
clinical trials need testing with randomized effectiveness
trials in naturalistic settings to see how they work “in
real life” [9].
Interpersonal psychotherapy (IPT) [10–12] and psy-
choeducational group therapy (PeGT) [13, 14] have
demonstrated efficacy as monotherapies. In this study
we aimed to test, in public mental health settings in the
Lohja district of Finland, the effectiveness of these two
structured, focused, time-limited antidepressant treat-
ment modalities (IPT, PeGT) relative to treatment as
usual (TAU). Finnish mental health services typically
treat highly comorbid MDD patients. We hypothesized
that IPT and PeGT would be more effective and would
consume less time and fewer resources than would
standard interventions. Given random allocation to con-
ditions and consistent treatment protocols for all partici-
pants in terms of pharmacotherapy we assumed equal
effectiveness of antidepressants in each treatment cell.
Methods
Study recruitment lasted from February 2004 through
March 2006.
Medline and PsychINFO surveys indicate that this is
the largest randomized clinical trial of brief psychother-
apies for patients with MDD and comorbid anxiety dis-
orders in Scandinavia.
Statistical analysis
Power analyses indicated group sample sizes of 32 were
needed to achieve a 91 % power to detect a 4 point dif-
ference (assuming a pooled standard deviation of 4.0) in
mean HAM-D scores from baseline to 3-month follow-
up between groups. An alpha level of .01 for a two-tailed
test was used in sample size calculations. To allow for
attrition, however, the aim was to enroll a total of 140-
160 patients (about 50 patients per group).
Baseline differences in demographic variables and the
depression measurements across the three treatment
groups were tested using chi-square tests, Kruskal-
Wallis test and 1-way analysis of variance. To comply
with the intention-to-treat principle in a setting with
high dropout rates, likelihood-based inference using
linear mixed models was employed to analyze treatment
effects. The main focus in mixed models was on the
treatment-time interaction (=the effectiveness of inter-
vention). Separate analyses assessed IPT-TAU, PeGT-
TAU, and IPT-PeGT comparisons. The modifying effect
of baseline depression severity and use of medication at
baseline on the effectiveness of intervention was tested
using modifier-treatment-time interaction. Unstructured
covariance structure was used in mixed models to ac-
count for the correlation between repeated measure-
ments. Only patients with baseline measurement and at
least one follow-up visit were included in longitudinal
analysis. All statistical analyses were performed using R
software [15].
Patient selection
All adult Finnish-speaking patients, ages 18-64, whose
referral documents to the Lohja and Vihti clinics noted
depressive symptoms, were invited to participate in a
diagnostic interview. The Lohja region, 60 km from
Helsinki, encompasses two cities and four rural counties;
its 79,000 inhabitants are two-thirds urban and one-
third rural. Two clinics provide the area’s mental health
outpatient services: the Lohja outpatient clinic and the
Vihti outpatient clinic. The study teams worked equally
in both clinics to ensure access for patients. All area re-
ferrals were funneled to the nearest clinic for assessment
and treatment. Referrals came from local primary health
care, occupational health care, and private general prac-
titioners. One study psychiatrist (H.S.) conducted the
screening assessments. Mental health outpatient clinic
treatment is provided gratis for all patients in Finland.
Diagnostic assessments
Patients had to fulfill ICD-10 diagnostic criteria [16] for
unipolar depression (F32-F33) and meet suitability re-
quirements for outpatient treatment. Diagnoses were
verified by the Diagnostic and Statistical Manual of
Mental Disorders 4th Edition (DSM-IV; [17]) utilizing
the Finnish translation [18] of the Mini International
Neuropsychiatric Interview (M.I.N.I.). Psychotic or se-
verely suicidal patients needing hospitalization were ex-
cluded, as were patients with alcohol dependence or
illicit substance abuse; however, patients were not ex-
cluded for anxiety disorders, alcohol harmful use or for
stable, chronic somatic illness. Patients with serious
acute somatic illness were referred elsewhere for appro-
priate treatment. Mental retardation was not an exclu-
sion criterion, but inability to read and write was.
Patients received a routine somatic check-up with basic
laboratory tests including thyroid function.
Trained doctors (four psychiatrists and one resident)
who were blinded to treatment assignment, treatment
condition for the post-treatment and follow-up ass-
essments served in the role of assessors and conducted
the diagnostic interviews and administered 17-item
Hamilton Rating Scale for Depression (HAM-D, [19]),
the Social and Occupational Functioning Assessment
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Scale (Sofas, [20]), and the Clinical Global Impression
of Severity and Change (CGI-s, CGI-c; [21]).
Depressive severity was assessed using the HAM-D
[19], with an inclusion threshold of ≥14 points. This was
the primary study outcome variable. The research proto-
col was approved by the Ethics Committee of Hospital
District of Helsinki and Uusimaa, Finland, in compliance
with the Declaration of Helsinki (approval number
20.1.2004/Dnro 517/E7/03).
After explaining the study protocol to patients, research
staff asked them for their written informed consent. Pa-
tients also received written information about the study.
Before randomization, those who had consented to par-
ticipate were assessed for possible need for antidepressant
medication or sick leave, according to guidelines from the
Instructions Regarding Depression: Current Care Guide-
line, 2004 www.kaypahoito.fi [22]. Although IPT and
PeGT have demonstrated antidepressant efficacy as
monotherapies, the Current Care Guideline for Depres-
sion recommends antidepressant medication in moderate
to severe ICD-10 depression. It recommends psychothera-
peutic interventions for mild and moderate depression,
but not as first-line treatment for severe depression.
Therefore, because TAU includes antidepressant medica-
tion, clinicians recommended such medication to all study
patients. Not all patients accepted this recommendation
or the offer of sick leave. National Health Insurance Re-
cords were used to verify medication purchases.
Screening and assessment personnel did not treat
study patients. The human resources expended for each
treatment modality was assessed by number of visits in
each group and hours of actual therapy.
Treatment trial
Patients entering the study were randomized to three
treatment arms: 1) IPT, 2) PeGT, or 3) TAU. IPT and
PeGT were alternatives to TAU. All patients were rec-
ommended antidepressant pharmacologic treatment. A
computer program randomly allocated 134 patients
equally across the treatment groups. Codes were kept in
separate, opaque envelopes, opened post-consent by the
research assistant, who then assigned patients to the
proper treatment protocol. The IPT treatment team
comprised two psychiatric nurses and one social worker;
the PeGT team had one psychologist and three psychi-
atric nurses. TAU was conducted by other outpatient
clinic staff members of comparable experience. Asses-
sors were blinded to treatment modality. Patients were
instructed not to describe their treatment to the raters.
Treatments
1) IPT, a time-limited, manualized [23, 24] psycho-
therapy, focuses on current interpersonal
problems. IPT reduces depressive symptoms and
improves interpersonal functioning. It uses a med-
ical model of depressive illness, relates symptoms
to a focal interpersonal problem area (grief, role
dispute, role transition, or interpersonal deficits),
helps patients understand their affects as useful
interpersonal environmental signals, and mobilizes
social supports.
2) PeGT is a psychoeducational self-treatment of
depression in group format. Therapists act as
coaches for groups of 4-6 patients. Lewinsohn and
colleagues created this treatment model and pub-
lished the “Control Your Depression” protocol in
1986 [13]. Koffert and Kuusi translated this manual
including a workbook into Finnish in 2002 [25].
3) TAU in Finnish public mental health clinics typically
provides low-frequency individual supportive psycho-
therapy of variable duration conducted by a psychiatric
nurse, and antidepressant medication from a psych-
iatrist who sees the patient in brief medication visits
every 4-6 weeks. TAU personnel were advised to
implement treatment as they usually would. The
doctors who recommended sick leave and possible
medication during the treatment phase were blinded to
treatment modality and did not participate in treating
the patients they rated.
The IPT and PeGT therapies comprised 10 therapeutic
sessions. IPT usually comprises 12-16 weekly sessions but
has been delivered in doses as low as 8 sessions [26, 27].
The 10-session approach was deemed suitable based on
estimation that TAU provided a mean of 10 therapeutic
sessions per patient, including pharmacotherapy sessions.
The 10-session acute therapy was planned to occur over
10-12 weeks in IPT and PeGT, with more variable time
and sessions in TAU. This acute treatment phase had a
12-month follow-up.
Training
Three psychiatrists (two with over 15 years and one with
over 7 years of experience) and one psychiatric resident
(with over 5 years of experience) served as assessors.
Training in standardized use of the M.I.N.I., HAM-D-
17, CGI-c, and SOFAS included a lecture by Finnish ex-
perts and practical training including videotaped patient
cases. Regular rater meetings maintained diagnostic and
rating skills.
Therapists
The four IPT therapists were trained with a set of theor-
etical lectures and then completed three supervised pilot
training cases. Supervision was executed by two psychia-
trists both with over 5 years of experience in IPT
Saloheimo et al. BMC Psychiatry  (2016) 16:131 Page 3 of 9
treatment and supervision. Three psychiatric nurses and
one clinical psychologist received training for PeGT by
reading the protocol and taking the “Control Your De-
pression” course. They were led by psychiatrist who has
over 5 years’ experience with this treatment and co-
translated the book into Finnish [25]. Study personnel
were recruited from the permanent clinic staff who had
expressed interest in the study and had at least 5 years
of clinical experience. They were blinded to treatment
modality before recruitment and were assigned ran-
domly to one of the therapy arms and then trained in
IPT or PeGT. This procedure was intended to maximize
acquisition of psychotherapists in this region. TAU ther-
apists were advised to implement “routine” TAU. The
mean age of IPT therapists was 45 years, and PeGT
therapists, 44 years. All had more than 5 years’ experi-
ence in treating depressed patients. TAU therapists had
similar experience.
Both treatment modalities continued group supervision
monthly throughout the trial. For PeGT, patient comple-
tion of the workbook was considered adherence to the
therapy model. For IPT, 40 % of therapy sessions were
taped, and 20 % of the taped sessions were reviewed in
therapist groups with subsequent commentary by the
supervisor to confirm fidelity to the treatment. Therapist
adherence was not formally measured.
Assessment and follow-up
Assessments were conducted at baseline, 1.5 months,
3 months, 6 months and 1 year. The primary outcome
point for effectiveness was immediately post-treatment
(3 months).
A key objective was to assess effectiveness of the differ-
ent treatments. Response was defined a priori as ≥50 %
decrease in baseline HAM-D-17 score, and remission as
HAM-D-17 score ≤7. Other comparisons included the
Clinical Global Impression Severity and Improvement
(CGI-s, CGI-I) and the Social and Occupational Function-
ing Assessment Scale (SOFAS).
IPT and PeGT patients attending at least 7 therapy
sessions were considered completers. No such criterion
was applied to the TAU group because of natural vari-
ability in TAU attendance. We counted the number of
visits and actual personnel time contributed to therapy
and consultations in each cell.
Results
Figure 1 shows the patients selection, randomization
and attrition of the 134 patients in this study. Of 165 pa-
tients with MDD diagnoses subsequently verified by
M.I.N.I., 31 (19 %) refused study participation (Table 2).
The 134 remaining patients were randomized to the
three study groups IPT group consisting 46, GT group
42 and TAU group 46 patients at baseline (Fig. 1). In
IPT, 31 (67 %) patients completed the 12-month follow-
up, compared with 21 (50 %) in PeGT and 28 (61 %) in
TAU (χ2(2) = 2.80, p = .25).
The mean number of total visits for psychiatric treat-
ment was 12.5 (SD 3.4) in IPT, 11.1 (SD 2.5) in PeGT,
and 14.6 (SD 9.3) in TAU. No statistically significant dif-
ferences appeared across the study groups (F(2,77) =
2.01, p = .14). We lacked access to data from services
outside the public sector (e.g., health centers, private
physicians).
Median personnel time spent on psychotherapy or
TAU counseling among study completers did not differ
significantly by group: 10.0 (IQR 1.0) hours for IPT, 12.1
(IQR 4.9) hours for PeGT, and 12.0 (IQR 11.5) hours for
TAU (χ2(2) = 0.78, p = .68, Kruskal-Wallis test). PeGT
was implemented in nine groups (mean 3.47 patients
per group) to minimize delay, with two therapists con-
ducting the 2-hour sessions.
Sample demographics
Baseline analyses revealed no significant group differ-
ences in age, sex or marital status (Table 1). PeGT pa-
tients had significantly higher employment level than
TAU patients (χ2(1) = 7.98, p = .005).
Refuser demographics
Comparisons of demographic characteristics of study re-
fusers with study enrollees revealed statistically signifi-
cant differences on HAM-D scores and age: study
refusers were younger and slightly less depressed (mean
difference 1.6 HAM-D points) (Table 2).
Comorbidity
Summing comorbid diagnoses for any anxiety disorder
and substance-related disorders revealed no statistically
significant differences between study patients and re-
fusers. Comorbidity rates for any anxiety disorder were
57 % among enrollees vs. 58 % among study refusers
(χ2(1) = 0.00, p = .95); and 59 % in IPT, 55 % in PeGT,
and 56 % in TAU (χ2(2) = 0.14, p = .93). Median AUDIT
scores measuring alcohol and substance abuse were 3.0
(IQR 7.0) for IPT, 3.0 (IQR 6.0) for PeGT, and 4.0 (IQR
5.5) for TAU (χ2(2) = 0.44, p = .80, Kruskal-Wallis test).
In AUDIT scoring, 4 of 40 points indicates elevated risk
for harmful use of alcohol in men; for women, the cutoff
is 3 of 40.
Pharmacotherapy for depression and patient treatment
attendance
We documented antidepressants and adjunct pha-
rmacologic therapy in all study groups. This was per-
formed by using doctors’prescriptions and National
Health Insurance statistics to clarify compliance. In all
three study groups there were patients who refused
Saloheimo et al. BMC Psychiatry  (2016) 16:131 Page 4 of 9
pharmacotherapy.(We did not attempt blood-level test-
ing.) Adequate dosage was defined by Käypä Hoito
(Finnish Guidelines for the treatment of Patients with
Depression). The Guidelines recommend antidepressant
pharmacotherapy to patients who are suffering moderate
to severe depression according to ICD-10 criteria. All
patients in this study were recommended to receive anti-
depressant treatment. Doctors’ prescriptions also
followed the Guidelines. Two patients in each cell used
quetiapine and risperidone as adjuvant pharmacother-
apy. We found no statistically significant differences
concerning types or combinations of antidepressants.
We divided the groups according to antidepressant
medication use during the treatment and 12-month
follow-up phases: 1) patients not using antidepressants; 2)
patients who filled one to three monthly prescriptions,
considered a proxy for suboptimal pharmacological adher-
ence; and 3) patients who filled four or more prescrip-
tions, considered a proxy for substantial pharmacologic
intervention. We assumed that monthly prescriptions
contained adequate antidepressant medication for the
period.
We measured antidepressant use by study patients at
3 months and 1 year, and by study completers over
1 year.
We found no statistically significant differences be-
tween study groups at 3 months (χ2 (4) = 2.61, p = .63)
or at 1 year (χ2(4) = 5.96, p = .20); however, there were
statistically significant differences among study com-
pleters (Table 3): Four or more purchased packages
which was considered as substantial pharmacological ad-
herence were seen by 21 (91 %) patients in PeGT, 24
(67 %) in IPT and 16 (50 %) in TAU groups (χ2(4) =
13.92, p = .007 for the overall differences among treat-
ment groups).
Dropout
We studied retention rate and reasons for attrition. Dur-
ing the 12-month follow-up, dropout rates were 33 % in
IPT, 50 % in PeGT and 39 % in TAU groups (χ2(2) =
Fig. 1 Referrals, pre-screening, screening, randomization, and attrition in the trial
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2.80, p = .25). Five patients in IPT, eight in PeGT and
seven in TAU dropped out after baseline measurement
without any follow-up visits (χ2(2) = 1.16, p = .56). One
patient in IPT, six in PeGT and none in TAU dropped
out after randomization but before the first treatment
session. Reanalysis of the data with an intent-to-treat
principle including these patients in longitudinal analysis
did not change the findings. Reason unknown (unable to
contact patient) was the most common attrition occur-
rence, applying to eight IPT, six PeGT, and five TAU pa-
tients. Psychiatric hospitalization or clinical deterioration
explained three IPT, two PeGT, and five TAU cases who
were classified as non-responders. Five patients in PeGT,
one in IPT, and two in TAU dropped out because of
subjective dissatisfaction, as reported in freely written
comments. Three IPT patients and three TAU patients
had incomplete follow-up because they relocated outside
the region. Two TAU patients reported lack of motiv-
ation for treatment. Five PeGT patients sought individ-
ual therapies after study intervention; these therapies
consisted of family counseling or private, individual
psychodynamic-oriented psychotherapy.
Outcome
Patients were categorized according to their HAM-D
scores at baseline as having moderate (≤20) or severe
(≥21) depression. The modifying effect of baseline depres-
sion severity (≤20 or 21≥) on the effectiveness of interven-
tion was tested using a linear mixed model. No significant
interaction effects of depression severity, treatment, and
time on HAM-D (F(8,108) = 1.11, p = .36), SOFAS
(F(8,108) = 0.57, p = .80) or CGI (F(8,108) = 0.68, p = .71)
were detected. Similarly, no significant interactions of
time, treatment, or use of medication at baseline on
HAM-D (F(8,108) = 0.87, p = .54), SOFAS (F(8,108) =
0.25, p = .98), or CGI (F(8,108) = 0.51, p = .85) were
detected. All treatment groups improved rapidly. Im-
mediately post-treatment, mean HAM-D score reduc-
tions were 9.1 (SD 6.4) for IPT, 8.3 (SD 6.3) for
PeGT, and 11.1 (SD 6.4) for TAU. The time-treatment
interaction in HAM-D score changes approached statistical
significance at 3, 6, and 12 months (F(4,184) = 2.23, p
= .067; F(6,263) = 1.74, p = .11, and F(8,340) = 1.68, p = .10,
respectively) (Fig. 2). PeGT was significantly more effective
Table 2 Refuser characteristics
Characteristics Total Refusers χ2 or t DF P-value
Sex 0.33 1 .57
Male 37 (28 %) 7 (23 %)
Female 97 (72 %) 24 (77 %)
Job situation 0.62 1 .43
Job 104 (78 %) 22 (71 %)
No job 30 (22 %) 9 (29 %)
Marital status 1.53 1 .22
Spouse 79 (59 %) 22 (71 %)
No spouse 55 (41 %) 9 (29 %)
Mean HAM-D (SD) 18.9 (3.8) 17.3 (2.5) 3.70 34 .0008
Mean age (SD) 41.9 (11.7) 36.3 (11.9) 2.37 45 .022
Table 1 Baseline clinical and demographic characteristics of the experimental groups
Characteristics IPT (N = 46) PeGT (N = 42) TAU (N = 46) χ2 or F DF P-value*
Sex 2.02 2 .36
Male 16 (35 %) 11 (26 %) 10 (22 %)
Female 30 (65 %) 31 (74 %) 36 (78 %)
Job situation 8.08 2 .018
Employed 36 (78 %) 38 (90 %) 30 (65 %)
Not employed1 10 (22 %) 4 (10 %) 16 (35 %)
Marital status 1.63 2 .44
Spouse 30 (65 %) 25 (60 %) 24 (52 %)
No spouse 16 (35 %) 17 (40 %) 22 (48 %)
Mean Age 43 (12.3) 42 (10.1) 40 (125) 0.93 2/131 .40
Mean HAM-D (SD) 18.7 (4.0) 19.3 (3.8) 18.9 (3.7) 0.31 2/131 .74
Mean CGI (SD) 4.5 (1.1) 4.5 (1.2) 4.6 (0.8) 0.08 2/131 .92
Mean JES2 (SD) 30.4 (6.1) 31.3 (6.7) 30.6 (6.7) 0.13 2/104 .88
Mean SOFAS (SD) 53.7 (9.5) 54.9 (10.3) 53.2 (8.8) 0.38 2/131 .68
Mean 15-D3 (SD) 0.73 (0.09) 0.76(0.07) 0.74 (0.09) 1.04 2/101 .36
* = p-value for the overall difference among treatment groups
DF = Degrees of freedom for χ2-test or 1-way ANOVA (DFnum/DFden)
1 = includes housewives, students, unemployed, non-military servants, and laid-off individuals
2 = 27 missing values
3 = 30 missing values
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than TAU at 3, 6, and 12 months (time-treatment inter-
action F(2,116) = 3.52, p = .033, F(3,162) = 2.91, p = .036,
and F(4,209) = 2.76, p = .029, respectively). No significant
difference in effectiveness was detected between IPT and
TAU, nor between IPT and PeGT. When linear mixed
models controlled for cumulative number of filled prescrip-
tions, the time-treatment interaction was significant at
12 months (F(8,338) = 1.99, overall p = .046; PeGT vs TAU
F(4,207) = 3.84, p = .0049; IPT vs TAU F(4,244) = 1.84, p
= .12). Because the number of filled prescriptions was not a
significant factor for HAM-D scores in mixed models, it
was removed from the final models.
All three groups showed over a 50 % mean decrease in
HAM-D scores from baseline to 6 months. At 3 months,
IPT and TAU showed a slightly (nonsignificantly) greater
decrease. Remission rates did not differ for any follow-
up interval: 42.4 % for IPT, 60.9 % for PeGT, and 42.3 %
for TAU s (χ2(2) = 2.27, p = .32 for overall difference) at
3 months; 58.8, 65.0, and 50.0 % (χ2(2) = 1.13, p = .57 for
overall difference) at 6 months; 51.6, 71.4, and 64.3 %
(χ2(2) = 2.24, p = .33 for overall difference) at 12 months.
The high dropout rate, especially in the PeGT (50 %)
and TAU (39 %) groups, lowered statistical power.
No differences were found in effectiveness of treat-
ment groups on SOFAS (time-treatment interaction,
F(8,338) = 0.56, p = .81) or on CGI (time-treatment
interaction, F(8,336) = 0.44, p = .90) during the 12-month
follow-up. No subject died or attempted suicide during
follow-up.
Discussion
The study describes outcomes for three treatment mo-
dalities for depressed (MDD) patients in specialized care
in a naturalistic, public sector setting. To our knowledge,
this is the largest psychotherapy effectiveness RCT for
major depressive disorder in the Nordic countries. We
hypothesized that well-organized, structured, and fo-
cused time-limited psychotherapies would be more ef-
fective and consume less resources than does the
standard intervention.
Results indicate that patients improved markedly and
quickly in all three treatment cells and maintained gains
at 12-month follow-up. Reassuringly, patients in the
Finnish public mental health system responded to stand-
ard antidepressant treatment; in fact, these patients fared
so well that addition of IPT and PeGT to the standard
pharmacotherapy options produced only a small further
advantage. This suggests a ceiling effect: there was little
further room to show improvement (Fig. 2). Some of
that additional advantage may reflect the fact that the
psychotherapy interventions seemed to improve medica-
tion adherence (Table 3).
The study maximized internal validity through diag-
nostic tools and randomization. It included high anxiety
disorder comorbidity in an externally valid, “real life”
setting, a municipal mental health secondary level unit.
Referrals were screened by psychiatrists, and assessors
were trained thoroughly to use the diagnostic instru-
ments. All treatments showed a 50 % or greater decrease
from baseline to 6 months, an outcome well within the
range of response in efficacy trials [28]. A statistically
significant difference emerged only between PeGT and
TAU groups and favored PeGT at follow-up time 3-
months to 12-months. This result partly supports the
primary hypothesis of effectiveness. The results encour-
aged a closer examination of the study population and
study personnel, the training procedure, quality control
of the treatment implementation, and other factors that
could influence the outcome. First: standard therapies
seem highly effective in the Finnish public mental health
system, particularly in light of the fact that most patients
suffering from MDD do not receive weekly psychother-
apy. Far from an inert control, TAU was an active, po-
tent comparator. In fact, there is growing criticism over
the use of TAU as a control comparator in clinical trials
[29, 30]. Burns [29] states that using TAU obscures find-
ings; furthermore, he asserts that the problem begins
with considering TAU as a control rather than an
equally or even more resource-demanding treatment.
TAU in this study seems not to have been a minimal
Fig. 2 Mean (standard error of the mean) 17-Item Hamilton Depression
Rating scale scores by treatment group at the baseline, and 1.5-, 3-, 6-,
and 12-month follow-up





N (%) N (%) N (%)
0 7 (19 %) 2 (9 %) 5 (16 %)
1-3 5 (14 %) 0 (0 %) 11 (34 %)
4 or more 24 (67 %) 21 (91 %) 16 (50 %)
χ2 = 13.92, df = 4, p = .007 for the overall differences by treatment group
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intervention. Treatment “contamination” may have oc-
curred; e.g., aspects of IPT and PeGT may have spilled
over inadvertently on public health ambulatory units
where some personnel used specific treatments while
others employed treatment as usual for depressed
patients.
Second: Preference differences may have played a role.
PeGT had the greatest attrition rate. Some patients, hav-
ing been randomized to PeGT, did not want to partici-
pate in a group treatment, and others left after one or
two sessions, feeling that group treatment did not suit
them. Other study subjects may have found group treat-
ment more attractive and motivating. This secondary
post-randomization self-selection might have influenced
the results in favor of PeGT. Conversely, PeGT patients
who dropped out may have been less likely to improve
than those who remained, so the former patients’ dis-
continuation could have caused inflation of results for
this group. Unfortunately, we did not assess patient pref-
erences for treatment.
Third: Variable use of antidepressant medication may
also have complicated the outcome results. Therapists
working in psychiatric ambulatory secondary care tend
to have quite positive attitudes towards pharmacologic
treatment. In PeGT groups this attitude may have en-
couraged patients to accept and maintain antidepressant
treatment. PeGT study completers were more likely to
use antidepressant pharmacotherapy in adequate dur-
ation and doses than were the other study modalities.
The group format seemed to yield better treatment com-
pliance with both psychotherapy and pharmacotherapy,
for patients who did not drop out.
Given the widespread use of antidepressant medication
in the treatment sample, this study appears underpow-
ered to find differences among the psychotherapies used.
Additionally, variable adherence by therapists may
have influenced the results. Monthly supervision of
structured therapeutic interventions is likely too infre-
quent for accurate monitoring of adherence, this also
may have influenced the results. Therapists were ran-
domly assigned to structured treatments: all personnel
in ambulatory units were interviewed and taught thera-
peutic tools, but therapists could not choose the therapy
they were asked to implement. This may have influenced
therapeutic allegiance. However, when interviewed after-
wards, all therapists reported satisfaction with their
treatment and said they still used the approach in their
everyday work.
Treatment attendance evaluation showed that TAU
group patients used non-significantly more services dur-
ing follow-up than did the structured treatment group
patients, consistent with one of our primary hypotheses.
One strength of time-limited therapies is that they en-
courage patients to regain remission. This study design
feature may have positively influenced the frequency and
coherent planning of TAU and thus minimized the dif-
ferences between study groups while being of benefit to
all study participants.
The study has several limitations. The high attrition
rate very likely influenced the results. We did not evalu-
ate patient treatment preferences at baseline, even
though preference often has been found to moderate
treatment results [31]. We did not evaluate therapist
preference but randomly assigned therapists to therapy
models. This study is underpowered to find differences
among psychotherapies because of the concomitant use
of antidepressant medication. Furthermore, interrater re-
liability was not assessed formally.
Conclusions
In this research we studied MDD patients with high co-
morbidities in three treatment modalities. According to
the primary outcome measure all patients benefited not-
ably. Secondary outcome measures showed parallel re-
sults. Improvement maintained over the 12-month
follow-up. To avoid statistical limitations future studies
should be performed with larger samples and take into
account both patients’ and therapists’ treatment prefer-
ences. Additionally, costs of antidepressant medication,
as well as secondary costs of side effects of biological
and psychotherapeutic interventions and of sick leave
and diminished social and functioning capacity should
be measured.
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